Patient access to biologics can be restricted in Western countries and virtually unreachable in developing countries. Regulatory legislation varies regionally, but most countries have now established or adopted formal biosimilar guidelines to pave the way for biosimilar approvals.

This section takes a closer look at biosimilar development at the regional level, including:

  • Affordability and access to biologics
  • Regulatory guidelines
  • Approvals
  • Potential savings
  • Future prospects.
Learn more about Regulatory Requirements >>